The DOI matches its Crossref record; 264 of the 264 references it cites were found in a registry or an index.
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae
Open accessAbstract
SUMMARY: Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is challenging, and some of the few active drugs are not available in many countries. For extended-spectrum β-lactamase and AmpC producers, carbapenems are the drugs of choice, but alternatives are needed because the rate of carbapenem resistance is rising. Potential active drugs include classic and newer β-lactam–β-lactamase inhibitor combinations, cephamycins, temocillin, aminoglycosides, tigecycline, fosfomycin, and, rarely, fluoroquinolones or trimethoprim-sulfamethoxazole. These drugs might be considered in some specific situations. AmpC producers are resistant to cephamycins, but cefepime is an option. In the case of carbapenemase-producing Enterobacteriaceae (CPE), only some “second-line” drugs, such as polymyxins, tigecycline, aminoglycosides, and fosfomycin, may be active; double carbapenems can also be considered in specific situations. Combination therapy is associated with better outcomes for high-risk patients, such as those in septic shock or with pneumonia. Ceftazidime-avibactam was recently approved and is active against KPC and OXA-48 producers; the available experience is scarce but promising, although development of resistance is a concern. New drugs active against some CPE isolates are in different stages of development, including meropenem-vaborbactam, imipenem-relebactam, plazomicin, cefiderocol, eravacycline, and aztreonam-avibactam. Overall, therapy of MDR-E infection must be individualized according to the susceptibility profile, type, and severity of infection and the features of the patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–264 of 264
Souli, M., Karaiskos, I., Masgala, A., Galani, L., Barmpouti, E., & Giamarellou, H. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-2936-5 · Cited by 59
Palacios-Baena, Z. R., Gutiérrez‐Gutiérrez, B., Calbo, E., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix606 · Cited by 59
Self-citationChang, Y.-Y., Chuang, Y.-C., Siu, L.-K. K., Wu, T.-L., Lin, J., Lu, P., Wang, J., Wang, L.-S., Lin, Y.-T., Huang, L., et al. (2014) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2014.05.010 · Cited by 58
Oliva, A., Gizzi, F., Mascellino, M. T., Cipolla, A., D’Abramo, A., D’Agostino, C., Trinchieri, V., Russo, G., Tierno, F., Iannetta, M., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.09.014 · Cited by 58
Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen
Kato, H., Hagihara, M., Hirai, J., Sakanashi, D., Suematsu, H., Nishiyama, N., Koizumi, Y., Yamagishi, Y., Matsuura, K., & Mikamo, H. (2017) · Drugs in R&D · doi:10.1007/s40268-016-0165-5 · Cited by 58
Souli, M., Rekatsina, P. D., Chryssouli, Z., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01271-08 · Cited by 57
Díaz, A., Ortiz, D., Trujillo, M., Garcés, C., Jaimes, F. A., & Restrepo, A. (2015) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000987 · Cited by 57
Harris, P. N. A., Mo, Y., Jureen, R., Chew, J., Ali, J., Paynter, S., Paterson, D. L., & Tambyah, P. A. (2015) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-015-0055-6 · Cited by 56
Zhang, Y., Lin, X., & Bush, K. (2016) · The Journal of Antibiotics · doi:10.1038/ja.2016.73 · Cited by 56
Hong, J. H., Clancy, C. J., Cheng, S., Shields, R. K., Chen, L., Doi, Y., Zhao, Y., Perlin, D. S., Kreiswirth, B. N., & Nguyen, M. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02411-12 · Cited by 55
Huang, C.-C., Chen, Y.-S., Toh, H. S., Lee, Y.-L., Liu, Y.-M., Ho, C., Lu, P., Liu, C.-E., Chen, Y., Wang, J.-H., et al. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(12)70003-1 · Cited by 55
Wiskirchen, D. E., Nordmann, P., Crandon, J. L., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01947-13 · Cited by 55
Veve, M. P., Wagner, J. L., Kenney, R. M., Grunwald, J. L., & Davis, S. L. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.014 · Cited by 55
Lee, S. Y., Kuti, J. L., & Nicolau, D. P. (2006) · Journal of Infection · doi:10.1016/j.jinf.2006.09.004 · Cited by 54
Haidar, G., Alkroud, A., Cheng, S., Churilla, T. M., Churilla, B. M., Shields, R. K., Doi, Y., Clancy, C. J., & Nguyen, M. H. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00869-16 · Cited by 54
Jakobsen, L., Cattoir, V., Jensen, K. S., Hammerum, A. M., Nordmann, P., & Frimodt‐Møller, N. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks224 · Cited by 53
Lob, S. H., Hackel, M., Kazmierczak, K. M., Hoban, D. J., Young, K., Motyl, M. R., Karlowsky, J. A., & Sahm, D. F. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.02.018 · Cited by 53
Gutiérrez‐Gutiérrez, B., Bonomo, R. A., Carmeli, Y., Paterson, D. L., Almirante, B., Martínez-Martínez, L., Oliver, A., Calbo, E., Peña, C., Akova, M., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv502 · Cited by 52
Self-citationKrapp, F., Grant, J. L., Sutton, S. H., Ozer, E. A., & Barr, V. O. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.01.018 · Cited by 51
Bassetti, M., Righi, E., Fasce, R., Molinari, M. P., Rosso, R., Biagio, A. D., Mussap, M., Pallavicini, F. B., & Viscoli, C. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm180 · Cited by 49
Tsai, H.-Y., Chen, Y., Tang, H.-J., Huang, C.-C., Liao, C., Chu, F., Chuang, Y.-C., Sheng, W., Ko, W., & Hsueh, P. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.07.006 · Cited by 48
Zhou, Y., Tao, M.-T., Feng, Y., Yang, R., Liao, X., Liu, Y., & Sun, J. G. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx038 · Cited by 48
Rodríguez-Martínez, J. M., Pichardo, C., García, I., Pachón-Ibáñez, M. E., Docobo-Pérez, F., Pascual, Á., Pachón, J., & Martínez-Martínez, L. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02020.x · Cited by 47
Albiero, J., Sy, S. K. B., Mazucheli, J., Caparroz‐Assef, S. M., Costa, B. B., Alves, J. L. B., Gales, A. C., & Tognim, M. C. B. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03099-15 · Cited by 47
Yoon, Y. K., Kim, J. H., Sohn, J. W., Yang, K., & Kim, M. J. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.12.017 · Cited by 47
MacVane, S. H., Crandon, J. L., Nichols, W. W., & Nicolau, D. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03267-14 · Cited by 46
Papp‐Wallace, K. M., Bajaksouzian, S., Abdelhamed, A. M., et al. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.02.003 · Cited by 44
Yang, C., Li, S.-H., Chuang, F., Chen, C., Lee, C.-H., Chen, J., Wu, C., & Lee, C. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-206 · Cited by 43
Diep, B. A., Hilliard, J. J., Le, V. T. M., Tkaczyk, C., Le, H. N., Tran, V. G., Rao, R. L., Dip, E. C., Franchi, E. P. L. P., Cha, P., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02456-16 · Cited by 43
Moreno, B. B., Fernández, I., García, V. P., Romero, I. S., Fernández, B. I., Ortega, M. Á. R., Carmona, S. A., Redondo, M. P., & Anuncibay, P. G. (2013) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2013.861608 · Cited by 42
Yu, W., Shen, P., Bao, Z., Zhou, K., Zheng, B., Ji, J., Guo, L., Huang, C., & Xiao, Y. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.03.011 · Cited by 42
Lee, C., Su, L., Chen, F., Tang, Y.-F., Li, C.-C., Chien, C., & Liu, J.-W. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.07.020 · Cited by 41
Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae
Pilmis, B., Parize, P., Zahar, J., & Lortholary, O. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2094-y · Cited by 41
Rice, L. B., Carias, L. L., & Shlaes, D. M. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.11.2663 · Cited by 41
Clancy, C. J., Hao, B., Shields, R. K., Chen, L., Perlin, D. S., Kreiswirth, B. N., & Nguyen, M. H. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01949-13 · Cited by 41
Polymyxins and Doripenem Combination Against KPC-Producing Klebsiella pneumoniae
Lee (2013) · Journal of Clinical Medicine Research · doi:10.4021/jocmr1220w · Cited by 41
Sy, S. K. B., Beaudoin, M., Zhuang, L., Löblein, K. I., Lux, C., Kissel, M., Tremmel, R., Frank, C., Strasser, S., Heuberger, J. A. A. C., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw082 · Cited by 40
Tseng, S., Wang, S., Ma, L., Wang, T.-Y., Yang, T.-Y., Siu, L.-K. K., Chuang, Y.-C., Lee, P., Wang, J., Wu, T., et al. (2017) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2017.03.003 · Cited by 39
Kaniga, K., Flamm, R. K., Tong, S.-Y., Lee, M., Friedland, I. R., & Redman, R. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01450-09 · Cited by 38
Lee, N., Huang, W.-H., Tsui, K.-C., Hsueh, P., & Ko, W. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.12.008 · Cited by 35
Wiskirchen, D. E., Koomanachai, P., Nicasio, A. M., Nicolau, D. P., & Kuti, J. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01253-10 · Cited by 35
Mavroidi, A., Katsiari, M., Likousi, S., Palla, E., Roussou, Z., Nikolaou, C., Maguina, A., & Platsouka, E. D. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2015.0282 · Cited by 34
Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock
Allou, N., Bouteau, A., Allyn, J., Snauwaert, A., Valance, D., Jabot, J., Bouchet, B., Galliot, R., Corradi, L., Montravers, P., et al. (2016) · Annals of Intensive Care · doi:10.1186/s13613-016-0211-z · Cited by 34
Nastro, M., Rodríguez, C. H., Monge, R., Zintgraff, J. C., Neira, L., Rebollo, M., Vay, C. A., & Famiglietti, A. M. R. (2013) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000136 · Cited by 33
Pitout, J. D. D., Le, P., Church, D. L., Gregson, D. B., & Laupland, K. B. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.04.023 · Cited by 33
Dalgıç, N., Sancar, M., Bayraktar, B., Dinçer, E., & Pelit, S. (2011) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2011.553241 · Cited by 32
Optimizing the Initial Amikacin Dosage in Adults
White, B. P., Lomaestro, B. M., & Pai, M. P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01032-15 · Cited by 30
Laishram, S., Anandan, S., Devi, B. Y., Munusamy, E., Priyanka, B., Bhuvaneshwari, T., Peter, J. V., Subramani, K., & Veeraraghavan, B. (2016) · Journal of Chemotherapy · doi:10.1080/1120009x.2016.1143261 · Cited by 30
Brasseur, A., Hites, M., Roisin, S., COTTON, F. J., Vincent, J., Backer, D. D., Jacobs, F., & Taccone, F. S. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv491 · Cited by 30
Wu, U., Chen, W., Yang, C.-S., Wang, J., Hu, F.-C., Chang, S., & Chen, Y. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.09.019 · Cited by 26
Rattanaumpawan, P., Werarak, P., Jitmuang, A., Kiratisin, P., & Thamlikitkul, V. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2284-1 · Cited by 26
Portsmouth, S., van Veenhuyzen, D., ECHOLS, R. M., et al. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1399 · Cited by 26
Fredborg, M., Søndergaard, T. E., & Wang, M. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.04.015 · Cited by 25
Dizbay, M., Özger, H. S., Karaşahin, Ö., & Karaşahin, E. F. (2016) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1506-157 · Cited by 24
Ni, W., Wei, C., Zhou, C., Zhao, J. F., Liang, B., Cui, J., Wang, R., & Liu, Y.-N. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01304 · Cited by 23
Han, S. B., Jung, S. W., Bae, E. Y., Lee, J. W., Lee, D., Chung, N., Jeong, D. C., Cho, B., Kang, J. H., Kim, H.-K., et al. (2014) · Microbial Drug Resistance · doi:10.1089/mdr.2014.0092 · Cited by 22
Huang, D. S., Yu, B. J., Diep, J. K., Sharma, R., Dudley, M. N., Monteiro, J., Kaye, K. S., Pogue, J. M., Abboud, C. S., & Rao, G. G. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00073-17 · Cited by 21
Hsieh, C., Lee, C.-H., Li, M.-C., et al. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.01.010 · Cited by 20
Kanazawa, S., Sato, T., Kohira, N., Ito-Horiyama, T., Tsuji, M., & Yamano, Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00576-17 · Cited by 17
Zhanel, G. G., Denisuik, A. J., Vashisht, S., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku149 · Cited by 12
Ozbek, B., Kara, E. M., Er, S., Özdamar, M., & Yılmaz, M. (2015) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2015.09.001 · Cited by 11
Salloum, N. A., Kissoyan, K. A. B., Fadlallah, S. M., Cheaito, K. A., Araj, G. F., Wakim, R. H., Kanj, S. S., Kanafani, Z. A., Dbaibo, G. S., & Matar, G. M. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00999 · Cited by 9
Daoud, Z., Sokhn, E. S., Azar, E., Masri, K., & Doron, S. (2014) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.3164 · Cited by 9
Song, S., Kim, C.-S., & Lim, D.-H. (2014) · Korean journal of urology · doi:10.4111/kju.2014.55.4.270 · Cited by 7
Cited by
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection
Castanheira, M., Simner, P. J., & Bradford, P. A. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab092 · Cited by 796
Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans
He, T., Wang, R., Liu, D., Walsh, T. R., Zhang, R., Lv, Y., Ke, Y., Ji, Q., Wei, R., Liu, Z., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0445-2 · Cited by 705
Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
Sheu, C.-C., Chang, Y.-T., Lin, S.-Y., Chen, Y.-H., & Hsueh, P.-R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00080 · Cited by 520
Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli
Sun, J., Chen, C., Cui, C.-Y., Zhang, Y., Liu, X., Cui, Z.-H., Ma, X.-Y., Feng, Y., Fang, L.-X., Lian, X.-L., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0496-4 · Cited by 484
Metadata
- Authors
- Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2018-04
- Volume
- 31
- Issue
- 2
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2786886659
- Cited by
- 704
- References
- 264
- FWCI
- 28.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.